Patient and graft characteristics
| Factors . | dUCB . | MRD . | MUD . | MMUD . | P . |
|---|---|---|---|---|---|
| No. of patients | 128 | 204 | 152 | 52 | NE |
| Median age at transplantation, y (range) | 25 (10-46) | 40 (12-67) | 31 (10-57) | 31 (10-51) | < .01 |
| Median weight, kg (range) | 72 (32-149) | 78 (12-67) | 76 (26-137) | 76 (34-145) | < .11 |
| Male | 72 (56%) | 120 (59%) | 95 (63%) | 31 (60%) | < .76 |
| Recipient CMV+ | 79 (62%) | 119 (58%) | 67 (44%) | 31 (60%) | < .01 |
| Diagnosis | < .01 | ||||
| ALL | 48 (38%) | 80 (39%) | 67 (44%) | 16 (31%) | |
| AML | 68 (53%) | 97 (48%) | 50 (33%) | 21 (40%) | |
| CML | 8 (6%) | 15 (7%) | 32 (21%) | 15 (29%) | |
| MDS | 4 (3%) | 12 (6%) | 3 (2%) | 0 (0%) | |
| High-risk disease | 65 (51%) | 112 (55%) | 93 (61%) | 35 (67%) | < .13 |
| Disease status at transplantation | < .01 | ||||
| Acute leukemia CR1 | 58 (45%) | 89 (44%) | 44 (29%) | 13 (25%) | |
| Acute leukemia CR2 | 42 (33%) | 42 (21%) | 42 (28%) | 11 (21%) | |
| Acute leukemia CR3+ | 16 (13%) | 46 (23%) | 31 (20%) | 13 (25%) | |
| CML 1st chronic phase | 5 (4%) | 3 (2%) | 4 (8%) | 5 (4%) | |
| CML accelerated phase | 3 (2%) | 12 (6%) | 17 (11%) | 11 (21%) | |
| Stem cell source | NE | ||||
| BM | NA | 17 (8%) | 64 (42%) | 18 (35%) | |
| PBSCs | NA | 187 (92%) | 88 (58%) | 34 (65%) | |
| dUCB | 128 (100%) | NA | NA | NA | |
| Nucleated cell dose (108/kg) | 0.4 (0.2-3.0) | 8.6 (1.6-22.2) | 2.0 (1.1-14.2) | 1.7 (1.6-1.9) | < .01 |
| HLA-matching* | NE | ||||
| 8/8 | NA | NA | 152 | NA | |
| 7/8 | NA | NA | NA | 52 | |
| 6/6 | NA | 204 | NA | NA | |
| 6/6 + 6/6 | 5 (4%) | NA | NA | NA | |
| 6/6 + 5/6 | 4 (3%) | NA | NA | NA | |
| 6/6 + 4/6 | 1 (1%) | NA | NA | NA | |
| 5/6 + 5/6 | 41 (32%) | NA | NA | NA | |
| 5/6 + 4/6 | 20 (16%) | NA | NA | NA | |
| 4/6 + 4/6 | 57 (45%) | NA | NA | NA | |
| Transplant center | < .01 | ||||
| FHCRC | 24 (19%) | 110 (54%) | 138 (91%) | 50 (96%) | |
| UM | 104 (81%) | 94 (46%) | 14 (9%) | 2 (4%) | |
| Median follow-up, y (range) | 2.1 (0.4-6.9) | 3.0 (0.4-7.5) | 4.2 (0.3-8.1) | 4.8 (2.0-7.5) | < .01 |
| Factors . | dUCB . | MRD . | MUD . | MMUD . | P . |
|---|---|---|---|---|---|
| No. of patients | 128 | 204 | 152 | 52 | NE |
| Median age at transplantation, y (range) | 25 (10-46) | 40 (12-67) | 31 (10-57) | 31 (10-51) | < .01 |
| Median weight, kg (range) | 72 (32-149) | 78 (12-67) | 76 (26-137) | 76 (34-145) | < .11 |
| Male | 72 (56%) | 120 (59%) | 95 (63%) | 31 (60%) | < .76 |
| Recipient CMV+ | 79 (62%) | 119 (58%) | 67 (44%) | 31 (60%) | < .01 |
| Diagnosis | < .01 | ||||
| ALL | 48 (38%) | 80 (39%) | 67 (44%) | 16 (31%) | |
| AML | 68 (53%) | 97 (48%) | 50 (33%) | 21 (40%) | |
| CML | 8 (6%) | 15 (7%) | 32 (21%) | 15 (29%) | |
| MDS | 4 (3%) | 12 (6%) | 3 (2%) | 0 (0%) | |
| High-risk disease | 65 (51%) | 112 (55%) | 93 (61%) | 35 (67%) | < .13 |
| Disease status at transplantation | < .01 | ||||
| Acute leukemia CR1 | 58 (45%) | 89 (44%) | 44 (29%) | 13 (25%) | |
| Acute leukemia CR2 | 42 (33%) | 42 (21%) | 42 (28%) | 11 (21%) | |
| Acute leukemia CR3+ | 16 (13%) | 46 (23%) | 31 (20%) | 13 (25%) | |
| CML 1st chronic phase | 5 (4%) | 3 (2%) | 4 (8%) | 5 (4%) | |
| CML accelerated phase | 3 (2%) | 12 (6%) | 17 (11%) | 11 (21%) | |
| Stem cell source | NE | ||||
| BM | NA | 17 (8%) | 64 (42%) | 18 (35%) | |
| PBSCs | NA | 187 (92%) | 88 (58%) | 34 (65%) | |
| dUCB | 128 (100%) | NA | NA | NA | |
| Nucleated cell dose (108/kg) | 0.4 (0.2-3.0) | 8.6 (1.6-22.2) | 2.0 (1.1-14.2) | 1.7 (1.6-1.9) | < .01 |
| HLA-matching* | NE | ||||
| 8/8 | NA | NA | 152 | NA | |
| 7/8 | NA | NA | NA | 52 | |
| 6/6 | NA | 204 | NA | NA | |
| 6/6 + 6/6 | 5 (4%) | NA | NA | NA | |
| 6/6 + 5/6 | 4 (3%) | NA | NA | NA | |
| 6/6 + 4/6 | 1 (1%) | NA | NA | NA | |
| 5/6 + 5/6 | 41 (32%) | NA | NA | NA | |
| 5/6 + 4/6 | 20 (16%) | NA | NA | NA | |
| 4/6 + 4/6 | 57 (45%) | NA | NA | NA | |
| Transplant center | < .01 | ||||
| FHCRC | 24 (19%) | 110 (54%) | 138 (91%) | 50 (96%) | |
| UM | 104 (81%) | 94 (46%) | 14 (9%) | 2 (4%) | |
| Median follow-up, y (range) | 2.1 (0.4-6.9) | 3.0 (0.4-7.5) | 4.2 (0.3-8.1) | 4.8 (2.0-7.5) | < .01 |
NE indicates not evaluable; CMV+, cytomegalovirus seropositive; CR1, first complete remission; CR2, second complete remission; CR3+, third completed remission, primary induction failures and active leukemia; and NA, not applicable.
As defined in “Study design and patient selection,” the degree of HLA-matching varies depending on the donor type.